European Commission launches antitrust investigation into Zoetis for potential EU competition rule violations regarding rival dog pain medicine.
The European Commission has launched a formal antitrust investigation into US animal health firm Zoetis over possible breaches of EU competition rules. The company is suspected of preventing the market launch of a rival medicine to treat chronic pain in dogs, by halting the development of an alternative product in its pipeline. The investigation relates to Zoetis' Librela, the only monoclonal antibody drug approved in Europe to treat osteoarthritis pain in dogs.
March 26, 2024
12 Articles